Skip to main content

Bronte Capital Management Pty Ltd.

Position in REGN — Regeneron Pharmaceuticals, Inc.

CIK 1471085 Bondi Junction, C3

Position in REGN

as of Mar 31, 2026 · filed Apr 27, 2026
Position Value
$133,502,147
-$2,939,769 QoQ
Shares Held
172,787
-2.3% QoQ
Ownership
0.165%
of shares outstanding
% of Portfolio
16.74%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Dec 2020
22 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in REGN Over Time

Shares Held

Position Value (USD)

Derivatives in REGN

reported options exposure · as of Mar 31, 2026
CallValue
$53,003,104
CallShares
68,600
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Bronte Capital Management Pty Ltd. holds $160,316,289 across 13 Biotechnology names. REGN ranks #1 (83.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 REGN
Regeneron Pharmaceuticals, Inc.
This page
172,787 $133,502,147

All Filings in REGN

Export CSV
24 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $133,502,147 172,787
2026-03-31 $53,003,104 68,600
2025-12-31 $45,771,891 59,300
2025-12-31 $136,441,916 176,768
2025-09-30 $101,367,722 180,283
2025-06-30 $98,631,750 187,870
2025-03-31 $98,110,941 154,693
2024-12-31 $108,831,914 152,783
2024-09-30 $144,064,032 137,042
2024-06-30 $146,570,337 139,454
2024-03-31 $139,631,311 145,073
2023-12-31 $127,721,810 145,421
2023-09-30 $116,401,108 141,442
2023-06-30 $99,385,578 138,316
2023-03-31 $112,053,602 136,373
2022-12-31 $102,973,217 142,723
2022-09-30 $101,384,442 147,175
2022-06-30 $88,190,093 149,189
2022-03-31 $97,092,253 139,017
2021-12-31 $82,388,099 130,460
2021-09-30 $75,177,880 124,224
2021-06-30 $65,611,135 117,469
2021-03-31 $28,098,365 59,387
2020-12-31 $9,204,694 19,053